InvestSMART

Tissue Repair Ltd (ASX:TRP)

ALERT: Price-sensitive ASX Announcement for TRP
Current share price for TRP : $0.086 -0.199 (-69.82%)+
Announcement
Release
30 Jan 2026 1:22PM
Price at Release
$0.285
Full Release
download
Summary
Tissue Repair Limited (ASX: TRP) provided a quarterly update for the period ending 31 December 2025. The company, focusing on developing wound healing agents, highlighted several key operational and financial developments. The cash position was reported as $8.229 million, with net operating cash outflows of $2.122 million primarily due to R&D and manufacturing costs. A significant aspect of their operations involves the Phase 3 trial for their lead drug TR987® aimed at treating chronic wounds, with a focus on achieving a meaningful increase in patient randomizations in 2026. Additionally, Tissue Repair is progressing with the commercialization of TR Pro+®, an aesthetic and medical procedure gel, with plans for broader market entry supported by partnerships and regulatory processes underway in the U.S., EU, and Southeast Asia. The report also detailed the use of funds versus the initial prospectus, showing varied allocation across development, trials, and commercialization activities.
Key Points
  • Net cash position as of 31 December 2025: $8.229 million.
  • Net operating cash outflows for the quarter: $2.122 million.
  • Focus on TR987® Phase 3 trial for chronic wounds.
  • Commercialization of TR Pro+® for aesthetic and medical procedures.
  • Partnership with Advanced Cosmeceuticals Pty Ltd.
  • Market strategy involves U.S., EU, and Southeast Asia.
  • Regulatory progress for global market entry with TR Pro+®.
  • Comparison of actual fund usage versus initial prospectus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.